Al-Shaheen, M., Zakaria, Z., Che Omar, M. (2023). The effect of end-stage renal failure and Cuperphan membrane on several biochemical parameters in hemodialysis patients at Al-Ramadi Teaching Hospital, Iraq. Alustath, 17(1), 72-84. doi: 10.37652/juaps.2023.178866
Mohammed R. Al-Shaheen; Zuraini Zakaria; Mohammed Tasyriq Che Omar. "The effect of end-stage renal failure and Cuperphan membrane on several biochemical parameters in hemodialysis patients at Al-Ramadi Teaching Hospital, Iraq". Alustath, 17, 1, 2023, 72-84. doi: 10.37652/juaps.2023.178866
Al-Shaheen, M., Zakaria, Z., Che Omar, M. (2023). 'The effect of end-stage renal failure and Cuperphan membrane on several biochemical parameters in hemodialysis patients at Al-Ramadi Teaching Hospital, Iraq', Alustath, 17(1), pp. 72-84. doi: 10.37652/juaps.2023.178866
Al-Shaheen, M., Zakaria, Z., Che Omar, M. The effect of end-stage renal failure and Cuperphan membrane on several biochemical parameters in hemodialysis patients at Al-Ramadi Teaching Hospital, Iraq. Alustath, 2023; 17(1): 72-84. doi: 10.37652/juaps.2023.178866

The effect of end-stage renal failure and Cuperphan membrane on several biochemical parameters in hemodialysis patients at Al-Ramadi Teaching Hospital, Iraq

Journal of University of Anbar for Pure Science
Volume 17, Issue 1, June 2023, Pages 72-84    PDF (635.83 K)
Document Type: Research Paper
DOI: 10.37652/juaps.2023.178866
Authors
Mohammed R. Al-Shaheen* 1; Zuraini Zakaria2; Mohammed Tasyriq Che Omar2
1Laboratory Department, Ramadi Teaching Hospital, Anbar Health Directorate, Ministry of Health, Iraq.
2Biological Section, School of Distance Education, Universiti Sains Malaysia (USM), Penang, Malaysia
Abstract
Purpose: Dialysis is a common treatment used for patients with chronic kidney disease (CKD), where a dialysis filter is used to remove waste products and excess fluid from the blood. The choice of dialysis filter can significantly impact the biochemical parameters of patients undergoing dialysis. This study aimed to investigate the effect of Cuprophane dialysis filter on the biochemical parameters of 100 chronic kidney disease patients undergoing three consecutive dialysis sessions at Ramadi Teaching Hospital in Iraq.Methods: Blood samples were collected from a total of 200 individuals, including 100 patients with CKD at Al-Ramadi Teaching Hospital in Iraq and 100 control subjects who were matched for age and gender as healthy control group. Samples were taken both before and immediately after three consecutive hemodialysis sessions for the CKD patients. Twenty blood parameters were measured for each sample using standard laboratory methods. The mean and standard deviation (SD) of each parameter were calculated, and ANOVA (Analysis of Variance) were used to determine the significance of differences between pre- and post-dialysis values.Results: Before dialysis, the patients had significantly higher levels of blood urea nitrogen (BUN), creatinine, potassium, glucose, uric acid, and total bilirubin, and significantly lower levels of serum total protein (STP) compared to the control group. After three dialysis sessions, the patients had significantly increased levels of serum cholesterol, triglycerides, amylase, and alkaline phosphatase (ALP), while the D.bilirubin level showed no significant difference compared to the control group.In contrast, after three dialysis sessions, the patients had significantly decreased levels of serum albumin, high-density lipoprotein (HDL), calcium, sodium, aspartate transaminase (AST), alanine transaminase (ALT), and total bilirubin (T.Bilirubin). Furthermore, the results indicated that the Cuprophane dialysis filter had differential effects on the levels of certain parameters before and after dialysis.Specifically, the dialysis membranes increased the levels of lactate dehydrogenase (LDH), decreased the levels of uric acid, serum potassium (S.K+), urea, and chloride (Cl-) to below the values of the control group, and reduced the high levels of Cr and Glu. These reductions brought the levels of creatinine and glucose to the control group levels after dialysis.Conclusion: In conclusion, the use of Cuprophane dialysis filter in chronic kidney disease patients led to significant changes in various biochemical parameters. The results highlight the importance of considering the type of dialysis filter used and monitoring the biochemical parameters of patients undergoing dialysis..
Keywords
Chronic kidney disease; End stage renal failure; Dialysis filter; Cuperphan membrane; Biochemical parameters
Supplementary Files
References
  • R. Vaidya and N. R. Aeddula, “Chronic renal failure,” in StatPearls [Internet], StatPearls Publishing, 2021.
  • C. C. Andreoli and C. Totoli, “Peritoneal dialysis,” Rev Assoc Med Bras, vol. 66, pp. s37–s44, 2020.
  • Tanaka et al., “Health-related quality of life on combination therapy with peritoneal dialysis and hemodialysis in comparison with hemodialysis and peritoneal dialysis: a cross-sectional study,” Peritoneal Dialysis International, vol. 40, no. 5, pp. 462–469, 2020.
  • Young, “Chronic Kidney Disease and the Dialysis Patient,” Preoperative Assessment: A Case-Based Approach, pp. 167–173, 2021.
  • Westphalen, S. Saadati, J. Bahig, H. Doan, A. Shoker, and A. Abdelrasoul, “Impact of Dialysis Clinical Operating Conditions on Human Serum Protein-Mediated Inflammatory Biomarkers Released in Patients Using Polyarylethersulfone Membranes,” Journal of Composites Science, vol. 6, no. 8, p. 226, 2022.
  • Huff, “How artificial kidneys and miniaturized dialysis could save millions of lives.,” Nature, vol. 579, no. 7798, pp. 186–189, 2020.
  • Van Pottelbergh, S. Bartholomeeusen, F. Buntinx, and J. Degryse, “The evolution of renal function and the incidence of end-stage renal disease in patients aged≥ 50 years,” Nephrology Dialysis Transplantation, vol. 27, no. 6, pp. 2297–2303, 2012.
  • Cozzolino, M. Mangano, A. Stucchi, P. Ciceri, F. Conte, and A. Galassi, “Cardiovascular disease in dialysis patients,” Nephrology Dialysis Transplantation, vol. 33, no. suppl_3, pp. iii28–iii34, 2018.
  • G. Vallianou, S. Mitesh, A. Gkogkou, and E. Geladari, “Chronic kidney disease and cardiovascular disease: is there any relationship?,” Curr Cardiol Rev, vol. 15, no. 1, pp. 55–63, 2019.
  • G. O. K. C.-M. Update, “KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD),” Kidney Int Suppl (2011), vol. 7, no. 1, p. 1, 2017.
  • M. Valdivielso, C. Jacobs-Cachá, and M. J. Soler, “Sex hormones and their influence on chronic kidney disease,” Curr Opin Nephrol Hypertens, vol. 28, no. 1, pp. 1–9, 2019.
  • R. de Oliveira Liberato, E. P. de Almeida Lopes, M. A. G. de Mattos Cavalcante, T. C. Pinto, I. F. Moura, and L. L. Júnior, “Liver enzymes in patients with chronic kidney disease undergoing peritoneal dialysis and hemodialysis,” Clinics, vol. 67, no. 2, pp. 131–134, 2012.
  • Kandi, R. Brignardello-Petersen, R. Couban, C. Wu, and G. Nesrallah, “Effects of medium cut-off versus high-flux hemodialysis membranes on biomarkers: a systematic review and meta-analysis,” Can J Kidney Health Dis, vol. 9, p. 20543581211067090, 2022.
  • -C. Tsai, Y.-P. Hsieh, S.-M. Tsai, C.-T. Kor, and P.-F. Chiu, “Superiority of albumin–globulin ratio over albumin to predict mortality in patients undergoing peritoneal dialysis,” Sci Rep, vol. 10, no. 1, p. 19764, 2020.
  • Comoglu et al., “Effects of Medium Cutoff Membranes on Pro-Inflammatory Cytokine and Oxidative Marker Levels in Patients with Sepsis Who Developed Acute Kidney Injury,” Blood Purif, vol. 51, no. 9, pp. 772–779, 2022.
  • J. H. Al-Saedy and H. R. A. Al-Kahichy, “The current status of hemodialysis in Baghdad,” Saudi Journal of Kidney Diseases and Transplantation, vol. 22, no. 2, p. 362, 2011.
  • Abdelrasoul, H. Westphalen, S. Saadati, and A. Shoker, “Hemodialysis biocompatibility mathematical models to predict the inflammatory biomarkers released in dialysis patients based on hemodialysis membrane characteristics and clinical practices,” Sci Rep, vol. 11, no. 1, p. 23080, 2021.
  • Lien, Conductiviy Measurements of Dialysis Efficiency in Predilution HDF Treatments. Skolan för datavetenskap och kommunikation, Kungliga Tekniska högskolan, 2009.
  • K. Thompson, Sampling, vol. 755. John Wiley & Sons, 2012.
  • Al-Obaidy, “Assessment of serum chemerin and serum visfatin levels in patients with ESRD in Kirkuk city,” University of Tikrit, 2017.
  • V Barreto et al., “Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease,” Kidney Int, vol. 77, no. 6, pp. 550–556, 2010.
  • Alfahdawi, “Evaluation of the association between lipid profile in patients with chronic kidney disease and cardiovascular disease,” University of Kufa, 2008.
  • Arshad, F. Manzoor, G. Jabeen, Z. Kanwal, U. Javed, and F. Butt, “Assessment of abnormalities in lipid profiles of patients with chronic kidney disease from different hospitals of Lahore, Pakistan: A case control study,” J Pak Med Assoc, vol. 70, no. 10, pp. 1838–1840, 2020.
  • Lodh, S. Lal, B. Goswami, P. Karmakar, and A. K. Parida, “Dyslipidemia in chronic renal failure: Cause or effect?,” Asian J Med Sci, vol. 7, no. 5, pp. 42–46, 2016.
  • Kumari, I. Dash, and M. Mangaraj, “Association of serum electrolyte with renal function, in diabetes mellitus-a pilot study,” Age (Omaha), vol. 62, no. 5.7, pp. 67–68, 2016.
  • R. Phukan and R. K. Goswami, “A study of serum sodium and calcium status in both hemodialysed and conservatively treated chronic kidney disease patients attending a tertiary care hospital of Assam, India,” Int J Res Med Sci, vol. 4, no. 12, pp. 5405–5410, 2016.
  • Shrimanker and S. Bhattarai, “Electrolytes,” 2019.
  • Li, Y. Li, and F. Zhou, “Association of serum potassium level with early and late mortality in very elderly patients with acute kidney injury,” Journal of Intensive Medicine, vol. 2, no. 01, pp. 50–55, 2022.
  • Mandai et al., “Association of serum chloride level with mortality and cardiovascular events in chronic kidney disease: the CKD-ROUTE study,” Clin Exp Nephrol, vol. 21, pp. 104–111, 2017.
  • Lai et al., “Study on the changes of blood glucose in hemodialysis patients with diabetes,” Rev Assoc Med Bras, vol. 67, pp. 822–827, 2021.
  • Barata, F. Cardoso, and T. Pereira, “Hyperuricemia in Chronic Kidney Disease: a role yet to be explained,” Port J Nephrol Hypertens, vol. 34, no. 1, pp. 30–35, 2020.
  • Y. Jeong et al., “Association of serum uric acid level with coronary artery stenosis severity in Korean end-stage renal disease patients [Volume 36, Issue 3, September 2017, Pages 282–289],” Kidney Res Clin Pract, vol. 37, no. 2, p. 180, 2018.
  • Sabouri, M. A. Aghaee, Z. Lotfi, H. Esmaily, M. Alizadeh, and H. M. Mozafari, “Evaluation of liver enzymes in end-stage renal disease patients on the renal transplant-waiting list in North-West of Iran,” Nephrourol Mon, vol. 12, no. 4, 2020.
  • B. Latiwesh et al., “Hepatic enzymes changes in chronic kidney disease patients-a need for modified reference values,” J Evolution Med Dent Sci, vol. 7, pp. 1949–1954, 2018.
  • Li, D. Liu, and Z. Liu, “Serum total bilirubin and progression of chronic kidney disease and mortality: a systematic review and meta-analysis,” Front Med (Lausanne), vol. 7, p. 549, 2021.
  • Y. Pai et al., “Association of serum globulin with all-cause mortality in incident hemodialysis patients,” Nephrology Dialysis Transplantation, vol. 37, no. 10, pp. 1993–2003, 2022.
  • Fujikawa et al., “Prognostic impact of preoperative albumin–to–globulin ratio in patients with colon cancer undergoing surgery with curative intent,” Anticancer Res, vol. 37, no. 3, pp. 1335–1342, 2017.
  • -P. Wu, Y.-P. Hsieh, C.-T. Kor, and P.-F. Chiu, “Association between albumin–globulin ratio and mortality in patients with chronic kidney disease,” J Clin Med, vol. 8, no. 11, p. 1991, 2019.
  • Pal and L. Mandal, “Serum Amylase in Patients of Chronic Kidney Disease Stage Three to Stage Five,” Birat Journal of Health Sciences, vol. 3, no. 2, pp. 403–407, 2018.
  • F. Mahomoodally and H. Nugessur, “Pre-and Post-Dialysis Correla ons of Serum α-Amylase, Crea nine and Urea in Chronic Renal Failure Pa ents,” Journal of Medical Research and Development (JMRD), pp. 151–160, 2014.
  • Zhang and L. Shi, “Serum lactate dehydrogenase level is associated with in-hospital mortality in critically Ill patients with acute kidney injury,” Int Urol Nephrol, pp. 1–8, 2021.
  • Yoon, S. Thapa, R. D. Chow, and B. G. Jaar, “Hemolysis as a rare but potentially life-threatening complication of hemodialysis: a case report,” BMC Res Notes, vol. 7, no. 1, pp. 1–4, 2014.
  • Mahawar, D. Thadani, G. G. Kaushik, A. Makwana, and S. Maheshwari, “EVALUATION OF SERUM ALKALINE PHOSPHATASE LEVEL IN NON-DIABETIC CHRONIC KIDNEY DISEASE PATIENTS IN INDIAN POPULATION”.
  • Owaki, D. Inaguma, A. Tanaka, H. Shinjo, S. Inaba, and K. Kurata, “Evaluation of the relationship between the serum alkaline phosphatase level at dialysis initiation and all-cause mortality: a multicenter, prospective study,” Nephron Extra, vol. 7, no. 3, pp. 78–88, 2017.
  • Shantouf et al., “Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 6, pp. 1106–1114, 2009.
Statistics
Article View: 202
PDF Download: 100


Journal Management System. Powered by ejournalplus.com